ST LOUIS, Missouri, May 2 /PRNewswire-FirstCall/ -- SAFC Supply Solutions, a member of the Sigma-Aldrich Group , has announced the launch of a cluster of new Proligo Reagent products at the TIDES Oligonucleotide and Peptide Conference in Carlsbad, California. The new offerings include a line of four Pharmadite(TM)(1) amidites for oligo-based drugs, a TFA C6 Linker, and key additions to the existing line-up of RNA amidites.
Through its Proligo Reagents brand, SAFC Supply Solutions is a leader in DNA and RNA phosphoramidites, and the ancillary reagents used in oligonucleotide synthesis. SAFC-Hamburg serves as the major manufacturing facility for these products.
New Pharmadite Amidites:
A key starting material for oligo-based drugs, Pharmadite amidites represent a new class of standard protected DNA phosphoramidites with a highly controlled impurity profile, exceptional overall purity, and non-animal derived starting materials. Prepared from DMT-protected nucleosides and a phosphitylating agent, the new products include DMT-dA(bz) Pharmadite, DMT-dC(bz) Pharmadite, DMT-dG(ib) Pharmadite and DMT-dT Pharmadite.
The high level of control in the ISO 9001-certified manufacturing process at the SAFC-Hamburg production facility have allowed a purity specification of greater than or equal to 99.5% for these materials. Pharmadite products fulfil all the requirements for starting materials in the manufacture of active pharmaceutical ingredients as defined in the EMEA "Note for guidance on chemistry of the new active substance," (2) making them suitable building blocks for oligonucleotide drugs.
TFA-Hexylamino Linker:
Phosphoramidite technology is ideal for the modification of synthetic oligos with covalently attached linkers, and the new Proligo Reagents trifluoroacetyl-protected amino linker is offered with a C6 spacer.
The base labile TFA group is easily removed during cleavage and deprotection. The amino linker is coupled with standard synthesis protocols, identical to the coupling of DNA monomer phosphoramidites.
Standard RNA Amidites:
Four new products, including DMT-2'O-TBDMS-rA(bz), DMT-2'O-TBDMS-rC(ac), DMT-2'O-TBDMS-rG(ib) and DMT-2'O-TBDMS-rU, are now offered to the highly-specialised and evolving RNA market segment. These products complement the existing SAFC Proligo TAC-protected RNA amidites, allowing the choice between using standard synthesis protocols or fast deprotection chemistries.
Commenting on the new products, Dr. Andreas Wolter of SAFC Supply Solutions Proligo Reagents noted, "The new introductions at TIDES are strategic additions to a market-proven range. While carefully targeted for particular applications in the oligo market, they share the consistent quality, tight specifications and reliability required by our customers and traditionally available at our Hamburg manufacturing facility."
The former Proligo Group, acquired from Degussa, joined the SAFC family in April 2005. The business was originally established in Germany in 1986, with subsequent refinement for production of DNA and RNA phosphoramidite monomers.
(1) Pharmadite is a trademark of Sigma-Aldrich Biotechnology L.P.
(2) EMEA: European Medicines Agency, http://www.emea.eu.int
About SAFC: SAFC is the custom-manufacturing group within Sigma-Aldrich that focuses on both biochemical production and the manufacturing of complex, multi-step organic synthesis of APIs and key intermediates. Representing 25% of corporate sales, SAFC is now Sigma-Aldrich's second largest business unit and a major player in the pharma and biopharma fine chemicals sector. Its four operating units are SAFC Pharma; SAFC Supply Solutions (formerly SAFC Specialties); SAFC Biosciences and SAFC Hitech. With annual sales of US$425 million, SAFC is now one of the world's top 10 fine chemical companies.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 35 countries and has over 6,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to accelerating Customer success through leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at www.sigma-aldrich.com.
Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company' operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.
SAFCCONTACT: Dr. Frank Wicks, President, SAFC, +1-314-286-8008
